As a new year begins, plans are underway for the 8 th Annual Rare Disease Genomics Symposium to be held on February 26 th and 27 th. The two-day event will be virtual this year to limit the spread of ...

Plexiform neurofibromas are tumors that grow along nerves. That’s how they get their name: "neuro" means nerves, and "fibroma" is a type of tumor. These growths have nerve tissue and many different ...

A new preclinical model of pulmonary arterial hypertension (PAH) may lead to improved research and ultimately better therapies for this life-threatening problem, according to its developers, ...

Neurofibromatosis type 1 (NF1) is a genetic condition that raises your risk of tumors, including benign plexiform neurofibromas (PN), which grow along tissues that cover nerves. PN often can’t be ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements. The ...

Findings from the ReNeu trial showed treatment with mirdametinib resulted in statistically significant objective response rates. The Food and Drug Administration (FDA) has accepted for Priority Review ...

Neurofibromatosis type 1 (NF1) is a rare genetic disorder that affects the nervous system, causing tumors to form on nerves throughout the body. It is also known as Von Recklinghausen disease, named ...

CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...

A new preclinical model of pulmonary arterial hypertension (PAH) may lead to improved research and ultimately better therapies for this life-threatening problem, according to its developers. A new ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Mirdametinib is an investigational mitogen-activated ...